Everardo D Saad

Summary

Publications

  1. doi Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspects
    Everardo D Saad
    Dendrix Research, Sao Paulo, Brazil
    Acta Oncol 51:890-6. 2012
  2. pmc Endpoints in advanced breast cancer: methodological aspects & clinical implications
    Everardo D Saad
    Dendrix Research, Sao Paulo, Brazil
    Indian J Med Res 134:413-8. 2011
  3. doi Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials
    Everardo D Saad
    Dendrix Research, Sao Paulo, Brazil
    Cancer Treat Rev 38:807-14. 2012
  4. doi Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials
    Everardo D Saad
    Dendrix Research, Rua Joaquim Floriano, 72 24 Sao Paulo, Brazil 04534 000
    J Clin Oncol 28:1958-62. 2010
  5. doi Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
    E D Saad
    Dendrix Research, Hospital Sirio Libanes, Sao Paulo, Brazil
    Ann Oncol 21:7-12. 2010
  6. doi The geography of clinical cancer research: analysis of abstracts presented at the American Society of Clinical Oncology Annual Meetings
    E D Saad
    Dendrix Research Ltd, Sao Paulo, Brazil
    Ann Oncol 21:627-32. 2010
  7. doi Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined
    E D Saad
    Dendrix Research, Sao Paulo, Brazil
    Ann Oncol 20:460-4. 2009
  8. doi Literature review and practical aspects on the management of oxaliplatin-associated toxicity
    Paulo M Hoff
    Hospital Sirio Libanes, Sao Paulo, Brazil
    Clin Colorectal Cancer 11:93-100. 2012
  9. doi Formal statistical testing and inference in randomized phase II trials in medical oncology
    Everardo D Saad
    Dendrix Research Ltd, Sao Paulo, Brazil
    Am J Clin Oncol 36:143-5. 2013
  10. ncbi Primary systemic chemotherapy of invasive lobular carcinoma of the breast
    Artur Katz
    Centro Paulista de Oncologia and Hospital Albert Einstein, Sao Paulo, Brazil
    Lancet Oncol 8:55-62. 2007

Detail Information

Publications11

  1. doi Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspects
    Everardo D Saad
    Dendrix Research, Sao Paulo, Brazil
    Acta Oncol 51:890-6. 2012
    ..Determining the non-inferiority margin is an essential step in the design and interpretation of non-inferiority trials, and this margin should be preferably justified on clinical and statistical grounds...
  2. pmc Endpoints in advanced breast cancer: methodological aspects & clinical implications
    Everardo D Saad
    Dendrix Research, Sao Paulo, Brazil
    Indian J Med Res 134:413-8. 2011
    ..This brief review aims at helping clinicians in their daily need to interpret the literature and make informed treatment choices for patients with advanced breast cancer...
  3. doi Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials
    Everardo D Saad
    Dendrix Research, Sao Paulo, Brazil
    Cancer Treat Rev 38:807-14. 2012
    ..We assessed the frequency and correlates of both usage and gain in HRQOL endpoints in NSCLC phase III trials...
  4. doi Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials
    Everardo D Saad
    Dendrix Research, Rua Joaquim Floriano, 72 24 Sao Paulo, Brazil 04534 000
    J Clin Oncol 28:1958-62. 2010
    ..PPS represents nearly two thirds of patient survival after on-trial disease progression...
  5. doi Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
    E D Saad
    Dendrix Research, Hospital Sirio Libanes, Sao Paulo, Brazil
    Ann Oncol 21:7-12. 2010
    ..The other question is whether PFS sufficiently reflects clinical benefit to be considered a true end point in and of itself...
  6. doi The geography of clinical cancer research: analysis of abstracts presented at the American Society of Clinical Oncology Annual Meetings
    E D Saad
    Dendrix Research Ltd, Sao Paulo, Brazil
    Ann Oncol 21:627-32. 2010
    ..The American Society of Clinical Oncology Annual Meeting is the largest forum for presentation of clinical research in oncology. We quantified the contribution of countries and assessed correlates of their presence at such meetings...
  7. doi Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined
    E D Saad
    Dendrix Research, Sao Paulo, Brazil
    Ann Oncol 20:460-4. 2009
    ..Background: The growing availability of active agents makes the development of novel therapies increasingly complex and the choice of end points critical. We assessed the frequency of use of efficacy end points in advanced breast cancer...
  8. doi Literature review and practical aspects on the management of oxaliplatin-associated toxicity
    Paulo M Hoff
    Hospital Sirio Libanes, Sao Paulo, Brazil
    Clin Colorectal Cancer 11:93-100. 2012
    ..Other adverse events, such as gastrointestinal and liver toxicity, thrombocytopenia, and hypersensitivity reactions, are also reviewed in this article, and suggestions are made for their management...
  9. doi Formal statistical testing and inference in randomized phase II trials in medical oncology
    Everardo D Saad
    Dendrix Research Ltd, Sao Paulo, Brazil
    Am J Clin Oncol 36:143-5. 2013
    ..We sought to quantify the frequency of use of formal statistical testing or inference through the use of P values and confidence intervals (CIs) in randomized phase II trials...
  10. ncbi Primary systemic chemotherapy of invasive lobular carcinoma of the breast
    Artur Katz
    Centro Paulista de Oncologia and Hospital Albert Einstein, Sao Paulo, Brazil
    Lancet Oncol 8:55-62. 2007
    ..Invasive lobular carcinoma deserves to be investigated separately in prospective clinical trials to define the best treatment and prevention strategies...